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Quantitative Systems Pharmacology (QSP) is experiencing increased application in the drug discovery and development
process. Like its older sibling, systems biology, the QSP field is comprised of a mix of established disciplines and methods,
from molecular biology to engineering to pharmacometrics.1 As a result, there exist critical segments of the discipline that
differ dramatically in approach and a need to bring these groups together toward a common goal.
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This article provides a summary, conclusions, and actions
resulting from the symposium entitled “GPS for QSP: Where
We’ve Been, Where We Are and Where We’re Going,” which
took place during the Sixth Annual American Conference on
Pharmacometrics (ACoP6) in Washington, DC on October 6,
2015. The symposium sought to contextualize the current
status of QSP based on its multidisciplinary roots and its his-
torical successes and challenges in order to establish its next
direction. Like most fields, this area has evolved from inde-
pendent, innovative efforts rather than from an overarching,
strategic plan. While this diversity is largely responsible for
the success of QSP today, it essentially represents the begin-
ning of an emerging discipline. The goal of the session was to
explore how history has shaped QSP and to use that under-
standing to set a course for its advancement as a scientific
and practical discipline. The symposium included presenta-
tions by industrial, academic, and regulatory scientists
followed by a panel discussion that produced three main
themes as critical for the future success of QSP as a discipline.
These themes resulted in new goals within the International
Society of Pharmacometrics’ (ISoP) Special Interest Group
(SIG) on QSP to engage the community to address them.
THEME 1: BUILDING EFFECTIVE TEAMS
The first theme that developed from the symposium was
the need for effective integration of researchers working in
all aspects of QSP, within and across academic, industry,
and regulatory sectors. In order to truly optimize this newly
emerging discipline, establishing multidisciplinary teams to
bring together scientists with a variety of educational back-
grounds, including mathematics and engineering as well as
physical, biological, and pharmaceutical sciences, has been
shown to maximize results and impact. Without effective
team-building efforts, there is a risk that QSP practitioners
may be working in siloes with colleagues of similar
backgrounds and this may limit the opportunity for creative
and innovative problem solving.
Improved collaboration between QSP researchers can be
achieved through training, communication, and focused
efforts. Several ideas for the seamless integration of the fields
of “quantitative” and “systems” pharmacology were discussed,
including:
• Development of integrated (university-level) QSP training programs
that include components of experimentation, systems biology and
pharmacology, and pharmacometrics to prepare our next generation
of QSP practitioners. Such individuals may be well suited to lead a
path in seamlessly merging the concepts of ‘‘top-down’’ and
‘‘bottom-up’’ approaches by effectively hybridizing parts of pharma-
cometrics, systems biology, and QSP.
• Formation of small, cross-disciplinary QSP teams focused on
addressing key questions, gaining alignment with key stakeholders,
and informing drug discovery and development decisions, as
opposed to focusing on the model per se.
• Adoption of ‘‘middle-out’’ approaches as effective strategies to bridge
potential knowledge gaps between traditional systems biology and
pharmacometrics approaches.
• A cultural shift that rewards teamwork, encourages intellectual syner-
gy, and promotes alternative approaches that offer unique and previ-
ously unavailable solutions to problems.
• Enabling teams with real-time simulation and visualization tools to
facilitate effective discussions and model development as well as
enhancing their ability to share and drive decisions within broader
teams.
Considering these points, the QSP SIG has formed multidis-
cipline and multisector member-led working groups. Drawing
on expertise from academic, industry, and regulatory scientists
from various fields including engineering, pharmacometrics,
systems biology, and bioinformatics, these groups will focus
on the identification, collection, and sharing of experiences
and information to enable teams to successfully apply and
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integrate pharmacometrics and systems pharmacology analy-
ses. Through these cross-disciplinary interactions, we envision
that commonalities and complementary approaches will be
identified and educational materials developed to highlight
best practices for effective QSP team building.
THEME 2: BUILDING MUTUALLY BENEFICIAL
CROSS-SECTOR COLLABORATIONS
Like other scientific fields, QSP will benefit from a diversity of
perspectives and approaches. The speakers’ presentations
highlighted multiple opportunities related to establishing and
maintaining effective QSP collaborations among academic,
industrial, and regulatory groups. The panel discussion
explored how to improve these interactions, leading to several
key points:
• The issues facing industry are not widely known within the academic
sector, and nonindustry researchers may have limited exposure to
the complexities of the drug discovery and development process.
Effective education and communication are necessary to promote
successful collaborations.
• When statements-of-work are created, the respective goals of aca-
demic and industry researchers and key questions to be assessed
must be considered and clearly defined. Pursuing new knowledge in
tandem with pursuing a new therapy is necessary for collaboration
to be successful, but the task of effectively managing the integration
of such goals should not be underestimated.
• Industry has shown success in vertical integration (i.e., scaling sub-
cellular pathway models up to organism) but has lacked significant
success in horizontal model integration (broadening a network to
encompass a more comprehensive biological representation). Aca-
demic laboratories have shown promise in this area, thus yielding a
potential area for future collaborations.
• Because of the breadth of the science and wide range of expertise in
QSP, aspects of this work are developed across departments, such as
preclinical discovery, bioinformatics, and quantitative pharmacology
(PKPD) among others, and this is not consistent between companies.
QSP methods, approaches, and concepts can be enhanced by inte-
grating this spectrum of computational endeavors within each compa-
ny. Improved integration will also enhance external collaborations with
academic researchers and regulatory scientists.
• When a collaborative project is initially formalized, tangibles such as
publication rights and patent ownership should be addressed explic-
itly. Although these issues should ultimately be handled within an
individual collaboration agreement, the community should develop
best practices that can be widely accepted and promoted to ensure
key decisions are addressed during the formation of collaborations.
Considering these points, the QSP SIG has recognized
the need for efforts in education, communications, and
focused discussions dedicated to facilitating a better atmo-
sphere of collaboration between academia, industry, and
regulatory agencies. Much of this could be accomplished
via cross-sector programming and attendance at meetings
and conferences. Longer-term goals are sighted on target-
ing specific scientific needs in QSP that could be met via
avenues of collaboration like precompetitive consortia that
may also include regulatory agency participation.
THEME 3: BUILDING A COMMUNITY
The final theme that developed from the session was the need
to advance QSP as a scientific discipline, through community
efforts. The formation of the ISoP QSP SIG and our member-
led working groups are one step toward this goal. However,
there is simply too much to be done; a broad range of experi-
ence, ideas, and insight are necessary for the success and con-
tinued advancement of the field. To this end, the SIG is working
closely with QSP focus groups in other professional organiza-
tions, including the American Association of Pharmaceutical
Scientists (AAPS), American Society of Clinical Pharmacology
& Therapeutics (ASCPT), International Pharmaceutical Federa-
tion (FIP), and the UK QSP Network, to publish articles and
organize programming at keymeetings to continue engagement
within and outside the QSP community.
There are a number of questions we hope to address
through community-based efforts and consensus, including:
• What is the best way for industry to engage academia to begin a
productive dialog towards improved understanding of key needs in
pharmaceutical R&D?
• What is the most productive way for academia to engage with industry?
• How should scientists who approach problems using the methods of
QSP be trained for a career in industry?
• Will a cross-disciplinary curriculum emerge as a foundation for QSP
modeling, or are there advantages to developing collaborative teams
consisting of specialists in core competencies?
• What new software and tools, such as real-time simulation and visu-
alization, are needed to enable optimal impact of QSP?
• How can QSP data and models be made more accessible?
• What can be done to help pharmaceutical organizations optimally
employ QSP experts and gain the most return on investment in the
practice?
• How can industry promote and support seamlessly integrated, cross-
disciplinary QSP teams?
• How can we facilitate the adoption of QSP as a universally accept-
ed research paradigm that is applied across the pipeline?
CONCLUSION
The GPS for QSP symposium resulted in a forum for practi-
tioners and those interested in the discipline to describe and
debate open issues deemedmost important to its advancement.
Although many of the outstanding issues associated with QSP
were highlighted, the authors acknowledge there are important
issues that were not specifically focused on, such as use and
acceptance of QSPmodels in regulatory submissions and learn-
ing from the establishment of guidance and qualification stand-
ards from more settled disciplines, like physiologically based
pharmacokinetic modeling. We encourage interested readers to
become involved in the discussion and future of QSP. These
efforts require the active participation of QSPand pharmacomet-
rics communities to engage in and lead them to fruition. If inter-
ested, we encourage you to take action, including but not limited
to 1) contacting the authors of this article for more information on
getting involved with these efforts, 2) joining and becoming
involved in professional organizations focused on QSP as well
as ones specializing in disease areas, and 3) publishing articles
and presenting successes and highlighting areas for
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improvement. The next major public update on the progress and
continuing goals of this group is planned for ACoP8 in 2017.
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